HDL as a drug and nucleic acid delivery vehicle

Frontiers in Pharmacology

Volumn 6, Issue OCT, 2015, Pages 247-

  Lacko, Andras G ^a,b   Sabnis, Nirupama A ^a,b   Nagarajan, Bhavani ^a   McConathy, Walter J ^c  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b University of North Texas Health Science Center   (United States)

^c Lipomedics Inc   (United States)

Author keywords

Drug delivery; HDL; Lipoproteins; Nucleic acid delivery; Therapeutics

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN A1; CHOLESTEROL ESTER; DRUG CARRIER; GOLD NANOPARTICLE; HIGH DENSITY LIPOPROTEIN; LIPOSOME; MICRORNA; NANOPARTICLE; NUCLEIC ACID; SMALL INTERFERING RNA; TANSHINONE IIA; UNTRANSLATED RNA;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TRANSPORT; GENE THERAPY; HUMAN; HYDROPHOBICITY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PROTEIN STRUCTURE;

EID: 84949679605     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00247     Document Type: Article

References (58)

1. Bali, K. K., and Kuner, R. (2014). Noncoding RNAs: key molecules in understanding and treating pain. Trends Mol. Med. 20, 437-448. doi: 10.1016/j.molmed.2014.05.006
2. Bijsterbosch, M. K., Rump, E. T., De Vrueh, R. L. A., Dorland, R., van Veghel, R., Tivel, K. L., et al. (2000). Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation. Nucleic Acids Res. 28, 2717-2725. doi: 10.1093/nar/28.14.2717
3. Bozzuto, G., and Molinari, A. (2015). Liposomes as nanomedical devices. Int. J. Nanomed. 10, 975-999. doi: 10.2147/IJN.S68861
4. Connelly, M. A., and Williams, D. L. (2004). SR-BI and HDL cholesteryl ester metabolism. Endocr. Res. 30, 697-703. doi: 10.1081/ERC-200043979
5. Counsell, R. E., and Pohland, R. C. (1982). Lipoproteins as potential site-specific delivery systems for diagnostic and therapeutic agents. J. Med. Chem. 25, 1115-1120. doi: 10.1021/jm00352a001
6. Cruz, P. M., Mo, H., McConathy, W. J., Sabnis, N., and Lacko, A. G. (2013). The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics. Front. Pharmacol. 4:119. doi: 10.3389/fphar.2013.00119
7. Ding, Y., Wang, Y., Zhou, J., Gu, X., Wang, W., Liu, C., et al. (2014). Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis. Biomaterials 35, 7214-7227. doi: 10.1016/j.biomaterials.2014.05.009
8. Ditiatkovski, M., D'Souza, W., Kesani, R., Chin-Dusting, J., de Haan, J. B., Remaley, A., et al. (2013). An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice. PLoS ONE 8:e68802. doi: 10.1371/journal.pone.0068802
9. Dobrovolskaia, M. A., and McNeil, S. E. (2015). Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics. Expert Opin. Drug Deliv. 20, 1-13. doi: 10.1517/17425247.2015.1042857
10. Farooqi, A. A., Rehman, Z. U., and Muntane, J. (2014). Antisense therapeutics in oncology: current status. Onco Targets Ther. 7, 2035-2042. doi: 10.2147/OTT.S49652
11. Gomaraschi, M., Calabresi, L., Rossoni, G., Iametti, S., Franceschini, G., Stonik, J. A., et al. (2008). Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides. J. Pharmacol. Exp. Ther. 324, 776-783. doi: 10.1124/jpet.107.129411
12. Hovingh, G. K., Smits, L. P., Stefanutti, C., Soran, H., Kwok, S., de Graaf, J., et al. (2015). The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: the Modifying Orphan Disease Evaluation (MODE) study. Am. Heart. J. 169, 736-742. e1. doi: 10.1016/j.ahj.2015.01.008
13. Huang, H., Cruz, W., Chen, G., and Zhen, G. (2015). Learning from biology: synthetic lipoproteins for drug delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 7, 298-314. doi: 10.1002/wnan.1308
14. Jin, H., Lovell, J. F., Chen, J., Lin, Q., Ding, L., Ng, K. K., et al. (2012). Mechanistic insights into LDL nanoparticle-mediated siRNA delivery. Bioconjug. Chem. 23, 33-41. doi: 10.1021/bc200233n
15. Kader, A., and Pater, A. (2002). Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J. Control. Release 80, 29-44. doi: 10.1016/S0168-3659(01)00536-3
16. Kaur, I. P., Chopra, K., Rishi, P., Puri, S., and Sharma, G. (2014). Small RNAs: the qualified candidates for gene manipulation in diverse clinical pathologies. Crit. Rev. Ther. Drug. Carrier Syst. 31, 305-329. doi: 10.1615/CritRevTherDrugCarrierSyst.2014007943
17. Kim, Y., Fay, F., Cormode, D. P., Sanchez-Gaytan, B. L., Tang, J., Hennessy, E. J., et al. (2013). Single step reconstitution of multifunctional high-density lipoprotein-derived nanomaterials using microfluidics. ACS Nano. 7, 9975-9983. doi: 10.1021/nn4039063
18. Kootte, R. S., Smits, L. P., van der Valk, F. M., Dasseux, J. L., Keyserling, C. H., Barbaras, R., et al. (2015). Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. J. Lipid Res. 56, 703-712. doi: 10.1194/jlr. M055665
19. Kujiraoka, T., Nanjee, M. N., Oka, T., Ito, M., Nagano, M., Cooke, C. J., et al. (2003). Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on LCAT, PLTP, and CETP in plasma and peripheral lymph in humans. Arterioscler. Thromb. Vasc. Biol. 23, 1653-1659. doi: 10.1161/01.ATV.0000089328.23279.3F
20. Lacko, A. G., Nair, M., Paranjape, S., Johnson, S., and McConathy, W. J. (2002). High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res. 22, 2045-2049.
21. Lacko, A. G., Nair, M., Paranjape, M., Mooberry, M., and McConathy, W. J. (2006). Trojan horse meets magic bullet to spawn a novel, highly effective drug delivery model. Chemotherapy 52, 71-173. doi: 10.1159/000093268
22. Lacko, A. G., Nair, M., Prokai, L., and McConathy, W. J. (2007). Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs. Expert Opin. Drug Deliv. 4, 665-675. doi: 10.1517/17425247.4.6.665
23. Leman, L. J., Maryanoff, B. E., and Ghadiri, M. R. (2014). Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis. J. Med. Chem. 57, 2169-2196. doi: 10.1021/jm4005847
24. Lovell, J. F., Huynh, E., MacDonald, T. D., Lin, Q., and Zheng, G. (2011). A new endogenous and immunologically inert siRNA delivery vehicle for targeting the brain. Nanomedicine (Lond.) 6, 1157-1158.
25. Lund-Katz, S., and Phillips, M. C. (2010). High density lipoprotein structure-function and role in reverse cholesterol transport. Subcell. Biochem. 51, 183-227. doi: 10.1007/978-90-481-8622-8_7
26. McConathy, W. J., Nair, M. P., Paranjape, S., Mooberry, L., and Lacko, A. G. (2008). Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs 19, 183-188. doi: 10.1097/CAD.0b013e3282f1da86
27. McMahon, K. M., Foit, L., Angeloni, N. L., Giles, F. J., Gordon, L. I., and Thaxton, C. S. (2015). Synthetic high-density lipoprotein-like nanoparticles as cancer therapy. Cancer Treat. Res. 166, 129-150. doi: 10.1007/978-3-319-16555-4_6
28. Mooberry, L. K., Nair, N., Paranjape, S., McConathy, W. J., and Lacko, A. G. (2010). Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J. Drug Target. 18, 53-58. doi: 10.3109/10611860903156419
29. Ng, K. K., Lovell, J. F., and Zheng, G. (2011). Lipoprotein-inspired nanoparticles for cancer theranostics. Acc. Chem. Res. 144, 1105-1113. doi: 10.1021/ar200017e
30. Pandey, G., and Kanduri, C. (2015). Long noncoding RNAs and neuroblastoma. Oncotarget 6, 18265-18275. doi: 10.18632/oncotarget.4251
31. Pensado, A., Seijo, B., and Sanchez, A. (2014). Current strategies for DNA therapy based on lipid nanocarriers. Expert Opin. Drug Deliv. 11, 1721-1731. doi: 10.1517/17425247.2014.935337
32. Rader, D. J., Alexander, E. T., Weibel, G. L., Billheimer, J., and Rothblat, G. H. (2009). The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 50(Suppl.), S189-S194. doi: 10.1194/jlr. R800088-JLR200
33. Remaley, A. T., Thomas, F., Stonik, J. A., Demosky, S. J., Bark, S. E., Neufeld, E. B., et al. (2003). Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J. Lipid Res. 44, 828-836. doi: 10.1194/jlr. M200475-JLR200
34. Ryan, R. O., Forte, T. M., and Oda, M. N. (2003). Optimized bacterial expression of human apolipoprotein A-I. Protein Expr. Purif. 27, 98-103. doi: 10.1016/S1046-5928(02)00568-5
35. Sabnis, N., Bowman, W. P., and Lacko, A. G. (2015a). Lipoprotein based drug delivery: potential for pediatric cancer applications. World J. Pharmacol. 4, 172-179.
36. Sabnis, N., and Lacko, A. G. (2012). Drug delivery via lipoprotein-based carriers: answering the challenges in systemic therapeutics. Ther. Deliv. 3, 599-608. doi: 10.4155/tde.12.41
37. Sabnis, N., Nair, N., Israel, M., McConathy, W. J., and Lacko, A. G. (2012). Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. Int. J. Nanomed. 7, 975-983. doi: 10.2147/IJN.S28029
38. Sabnis, N., Pratap, S., Akopova, I., Bowman, P. W., and Lacko, A. G. (2013). Pre-clinical evaluation of rHDL encapsulated retinoids for the treatment of neuroblastoma. Front. Pediatr. 1:6. doi: 10.3389/fped.2013.00006
39. Sabnis, S., Sabnis, N. A., Raut, S., and Lacko, A. G. (2015). Magnetically guided drug delivery via reconstituted high density lipoprotein nanoparticles. SAJ Nanosci. Nanotechnol. 1, 1-11.
40. Schouten, D., van der Kooij, M., Muller, J., Pieters, M. N., Bijsterbosch, M. K., and van Berkel, T. J. (1993). Development of lipoprotein-like lipid particles for drug targeting: neo-high density lipoproteins. Mol. Pharmacol. 44, 486-492.
41. Shahzad, M. M., Mangala, L. S., Han, H. D., Lu, C., Bottsford-Miller, J., Nishimura, M., et al. (2011). Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 13, 309-319. doi: 10.1593/neo.101372
42. Steinberg, D. (1996). A docking receptor for HDL cholesterol esters. Science 271, 460-461. doi: 10.1126/science.271.5248.460
43. Su, F., Grijalva, V., Navab, K., Ganapathy, E., Meriwether, D., Imaizumi, S., et al. (2012). HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer. Mol. Cancer Ther. 11, 1311-1319. doi: 10.1158/1535-7163.MCT-11-0905
44. Thaxton, C. S., Daniel, W. L., Giljohann, D. A., Thomas, A. D., and Mirkin, C. A. (2009). Templated spherical high density lipoprotein nanoparticles. J. Am. Chem. Soc. 131, 1384-1385. doi: 10.1021/ja808856z
45. Tufteland, M., Ren, G., and Ryan, R. O. (2008). Nanodisks derived from amphotericin B lipid complex. J. Pharm. Sci. 97, 4425-4432. doi: 10.1002/jps.21325
46. Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., and Remaley, A. T. (2011). MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 13, 423-433. doi: 10.1038/ncb2210
47. Vickers, K. C., and Remaley, A. T. (2012). Lipid-based carriers of microRNAs and intercellular communication. Curr. Opin. Lipidol. 23, 91-97. doi: 10.1097/MOL.0b013e328350a425
48. Wang, J., Jia, J., Liu, J., He, H., Zhang, W., and Li, Z. (2013). Tumor targeting effects of a novel modified paclitaxel-loaded discoidal mimic high density lipoproteins. Drug Deliv. 20, 356-363. doi: 10.3109/10717544.2013.834418
49. Weinberg, R. B. (1987). Lipoprotein metabolism: hormonal regulation. Hosp. Pract. 22, 223-227.
50. Wolfrum, C., Shi, S., Jayaprakash, K. N., Jayaraman, M., Wang, G., Pandey, R. K., et al. (2007). Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol. 25, 1149-1157. doi: 10.1038/nbt1339
51. Yang, M., Jin, H., Chen, J., Ding, L., Ng, K. K., Lin, Q., et al. (2011). Efficient cytosolic delivery of siRNA using HDL-mimicking nanoparticles. Small 7, 568-573. doi: 10.1002/smll.201001589
52. Yang, S., Damiano, M. G., Zhang, H., Tripathy, S., Luthi, A. J., Rink, J. S., et al. (2013). Biomimetic, synthetic HDL nanostructures for lymphoma. Proc. Natl. Acad. Sci. U.S.A. 110, 2511-2256. doi: 10.1073/pnas.1213657110
53. Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., and Anderson, D. G. (2014). Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15, 541-555. doi: 10.1038/nrg3763
54. Zamanian-Daryoush, M., Lindner, D., Tallant, T. C., Wang, Z., Buffa, J., Klipfell, E., et al. (2013). The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects. J. Biol. Chem. 288, 21237-21252. doi: 10.1074/jbc. M113.468967
55. Zhang, Z., Cao, W., Jin, H., Lovell, J. F., Yang, M., Ding, L., et al. (2009). Biomimetic nanocarrier for direct cytosolic drug delivery. Angew. Chem. Int. Ed. Engl. 48, 9171-9175. doi: 10.1002/anie.200903112
56. Zhang, Z., Chen, J., Ding, L., Jin, H., Lovell, J. F., Corbin, I. R., et al. (2010). HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small 6, 430-437. doi: 10.1002/smll.200901515
57. Zhang, W., Li, J., Liu, J., Wu, Z., Xu, Y., and Wang, J. (2012). Tanshinone IIA-loaded reconstituted high density lipoproteins: atherosclerotic plaque targeting mechanism in a foam cell model and pharmacokinetics in rabbits. Pharmazie 67, 324-330.
58. Zhu, L., and Mahato, R. I. (2010). Lipid and polymeric carrier-mediated nucleic acid delivery. Expert Opin. Drug Deliv. 7, 1209-1226. doi: 10.1517/17425247.2010.513969